Clinical Trials Logo

Fatigue clinical trials

View clinical trials related to Fatigue.

Filter by:

NCT ID: NCT00138138 Completed - Prostate Cancer Clinical Trials

Psychostimulants for Fatigue in Prostate Cancer

Start date: October 2002
Phase: Phase 2
Study type: Interventional

Fatigue is one of the most common symptoms of prostate cancer. Fatigue is a lack of energy that makes it harder to do the things you normally do every day. Some symptoms of fatigue are: - feeling tired and/or weak; - having less interest in activities; - having trouble concentrating; - feeling "down"; - feeling exhausted for no clear reason. There are not many drugs that are helpful in treating fatigue. However, one group of medications does seem to be useful. In this study, we, the investigators at Memorial Sloan-Kettering Cancer Center, will be using a psychostimulant called Ritalin. The aim of this study is to see if this drug is helpful in treating fatigue in prostate cancer. We are also studying the side effects of this medication.

NCT ID: NCT00118378 Completed - HIV Infections Clinical Trials

Effectiveness of Modafinil for Treating Fatigue in Adults With HIV/AIDS

Start date: December 2004
Phase: Phase 4
Study type: Interventional

This study will determine whether modafinil (Provigil®), a medication approved for the treatment of narcolepsy, is effective in reducing fatigue in adults with HIV/AIDS.

NCT ID: NCT00113906 Completed - Fatigue Clinical Trials

Melatonin Treatment After Laparoscopic Cholecystectomy

Start date: March 2005
Phase: Phase 2/Phase 3
Study type: Interventional

Circadian disturbances occur after surgery. A double blinded, placebo controlled randomized clinical trial was made to investigate effects of melatonin on postoperative fatigue, sleep disturbances and general wellbeing.

NCT ID: NCT00112749 Terminated - Breast Cancer Clinical Trials

Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer

Start date: February 2005
Phase: Phase 2
Study type: Interventional

RATIONALE: Infliximab may help improve energy levels in patients who have undergone treatment for breast cancer. PURPOSE: This phase II trial is studying how well infliximab works in treating cancer-related fatigue in postmenopausal women who have undergone treatment for stage 0, stage I, or stage II breast cancer.

NCT ID: NCT00112515 Active, not recruiting - Depression Clinical Trials

Modafinil in Treating Fatigue in Patients With Cancer

Start date: February 2004
Phase: N/A
Study type: Interventional

RATIONALE: Modafinil may help relieve fatigue and improve quality of life in patients with cancer. PURPOSE: This clinical trial is studying how well modafinil works in treating fatigue in patients with cancer.

NCT ID: NCT00106795 Completed - HIV Infections Clinical Trials

Relationship Between Fatigue and Mitochondrial Damage in Patients With HIV/AIDS

Start date: March 22, 2005
Phase: N/A
Study type: Observational

This study will examine abnormalities in mitochondria (energy-producing machinery of cells) and in genes related to mitochondria in the blood cells, muscle, and fat of HIV-positive patients who are taking nucleoside reverse transcriptase inhibitors (NRTIs) and in patients not currently taking HIV medications, and compare the results to healthy volunteers. Many patients with HIV infection take NRTIs to help control the infection. These medications may damage cell mitochondria, possibly causing side effects such as fatigue. This study will explore the relationship between changes in mitochondria and related genes and patient reports of energy level, mood and quality of life. Healthy volunteers and HIV-infected patients between 18 and 55 years of age may be eligible for this study. Healthy volunteers must test negative for the HIV antibody. HIV-positive patients must have been diagnosed positive for at least 1 year. Patients who are taking antiretroviral therapy must have been taking the same drug regimen (with at least two NTRIs and no protease inhibitors) for at least 3 months. HIV positive patients not taking antiretroviral medication must not have had antiretroviral therapy for at least 1 year. Candidates are screened with a medical history, brief physical examination, blood and urine tests, and questionnaires related to mood and energy. Qualified volunteers will undergo the following procedures during three or four study visits: Visit 1 Complete history and physical examination, blood tests, and questionnaires about energy level, mood, and quality of life. Visit 2 Muscle and fat biopsy: Before the biopsy, blood is drawn to check blood counts and to test for pregnancy in women who can become pregnant. The biopsy is done on an outpatient basis in the operating room. The site of the biopsy (an area on the upper arm or upper leg) is numbed with an injection under the skin. A 1-inch incision is made over the muscle to be biopsied and a small sample of muscle tissue and small sample of fat are removed. The incision is then closed and bandaged. Following the biopsy, you will be monitored for about 4 hours in the clinic. Strenuous physical activity should be restricted in the week following biopsy to allow healing. Visit 3 Examination of biopsy site and possible apheresis: The biopsy site is examined for healing. Apheresis may be scheduled for this visit or for an extra visit between the biopsy and the final visit. This procedure for obtaining white blood cells for study is optional. For apheresis, blood is withdrawn from a needle placed in a vein in the arm and the white cells are separated from the rest of the blood. The white cells are extracted and the red cells and plasma are then returned to the body through a second needle.

NCT ID: NCT00096356 Completed - Breast Cancer Clinical Trials

Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer

CoQ10
Start date: August 27, 2004
Phase: Phase 1
Study type: Interventional

RATIONALE: Coenzyme Q10 is a vitamin that may be effective in relieving fatigue and depression in women who are undergoing chemotherapy for breast cancer. PURPOSE: This randomized clinical trial is studying how well coenzyme Q10 works in relieving treatment-related fatigue in women with breast cancer.

NCT ID: NCT00091169 Completed - Fatigue Clinical Trials

Levocarnitine in Treating Fatigue in Cancer Patients

Start date: December 16, 2005
Phase: Phase 3
Study type: Interventional

RATIONALE: Levocarnitine may help improve energy levels in cancer patients. PURPOSE: This randomized phase III trial is studying how well levocarnitine works compared to a placebo in treating fatigue in cancer patients.

NCT ID: NCT00075842 Completed - Fatigue Clinical Trials

(Valerian) for Improving Sleep in Patients With Cancer Receiving Adjuvant Therapy

Start date: August 2003
Phase: Phase 3
Study type: Interventional

RATIONALE: The herb Valeriana officinalis (valerian) may promote sleep. It is not yet known whether valerian is effective in improving sleep in patients who are receiving adjuvant therapy for cancer. PURPOSE: This randomized phase III trial is studying how well valerian improves the quality of sleep in patients who are receiving adjuvant therapy (radiation therapy, chemotherapy, or hormone therapy) for cancer.

NCT ID: NCT00060398 Completed - Prostate Cancer Clinical Trials

Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer

Start date: September 29, 2004
Phase: Phase 3
Study type: Interventional

RATIONALE: Epoetin alfa may stimulate red blood cell production and may help improve cancer-related anemia and fatigue. Steroid therapy with dexamethasone may increase the effectiveness of epoetin alfa. It is not yet known if epoetin alfa is more effective with or without dexamethasone in treating anemia-related fatigue in patients with prostate cancer. PURPOSE: This randomized phase III trial is studying epoetin alfa and dexamethasone to see how well they work compared to epoetin alfa alone in treating anemia-related fatigue in patients with prostate cancer that is refractory to treatment with hormone therapy.